Related Insights
Article
Can Chinese Phase I data from the West accelerate China drug development?
Mar 17, 2021
Article
Lessons from China and the United States on the use of RWE in regulatory submissions
Jul 19, 2021
Blog
A hybrid model supports globally diverse site participation for a retrospective cancer study
Jul 24, 2023
Podcast
Enabling Successful Sites, episode 1: Site Feasibility and Study Start-up Challenges
May 10, 2024
Blog
Highlights from ISMPP Asia Pacific Meeting 2021
Sep 20, 2021
Blog
New Real World Evidence leader in Asia/Pacific returns to Parexel with lessons learned from China adventure
Jan 13, 2023
Blog
Preparing for a new era in European Market Access
Jul 22, 2022
Blog
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
May 16, 2022
Article
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
May 10, 2022
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Article
Evidence Generation Strategy under Germany’s Digital Healthcare: Is More Better?
Aug 6, 2021